摘要
目的探讨伊马替尼治疗慢性髓性白血病（CML）过程中发生耐药的相关因素。方法回顾性分析2005年4月至2010年12月接受伊马替尼治疗的214例CML患者临床资料，随访患者治疗情况、疗效，分析影响耐药的各种因素。应用COX比例风险回归模型对影响耐药的各种因素进行单因素和多因素分析。结果截至随访终点，31例（14．5％）患者出现伊马替尼耐药，其中1例为加速期患者，2例为急变期患者；完全细胞遗传学反应（CCyR）率为69．2％，主要分子学反应（MMR）率为31．3％。以207例慢性期患者进行COX分析，单因素分析显示，治疗前病程、HGB水平、WBC、是否获得CCyR、是否获得MMR为伊马替尼耐药的影响因素。多因素COX回归分析表明，是否获得CCyR为伊马替尼耐药的独立影响因素。结论是否获得CCyR是伊马替尼治疗CML是否发生耐药的独立影响因素，且为保护因素。
Objective To explore efficacy of imatinib for patients with chronic myeloid leukemia （CML） and its resistance-related factors during the treatment. Methods The clinical data of 214 CML patients received imatinib were analyzed respectively in our hospital from April 2005 to December 2010. The therapy history and efficacy of regular follow-up and factors influencing drug resistance were analyzed. COX regression analysis was used to perform the univariate and multivariate analysis. Results Until the end of follow up, thirty-one patients （14.5%） occurred drug resistance. One of them was in accelerated phase （AP）, and two in blast phase（BP） ; 69.2% of patients achieved a complete cytogenetic response（ CCyR）, and 31.3% of patients achieved a major molecular response（MMR）. COX analysis was performed in 207 chronic phase （CP） patients. Univariate analysis showed that the course of disease before treatment, the hemoglobin count, the white blood cell count, whether achieved CCyR or not and whether achieved MMR or not were the influencing factors for imatinib resistance. Multivariate analysis showed that whether achieved CCyR or not was the independent factor for drug resistance. Conclusion Whether achieved CCyR or not is an independent factor and also a protective factor for imatinib resistance in patients with CML.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2013年第5期395-398,共4页
Chinese Journal of Hematology
基金
江苏高校优势学科建设工程资助项目及江苏省临床医学中心资助项目（ZX201102）
关键词
白血病
髓样
慢性
伊马替尼
多因素分析
Leukemia,myelogenous,chronic
Imatinib
Multivariate analysis
